Drugs / Edotecarin
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00072332 | Aug 2003 → Dec 2005 | esophageal cancer, gastric cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00087503 | Apr 2004 → Jun 2005 | gastric cancer | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00067314 | Jun 2003 → Jun 2007 | breast cancer, metastatic malignant neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00070031 | Jun 2003 → Apr 2006 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00068952 | Aug 2003 → Mar 2006 | glioblastoma | Pfizer | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Edotecarin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00087503 ↗ |
| Known as | Edotecarina | ChEMBL registry synonym — accepted as the source's own label CHEMBL435191 ↗ |
| Known as | Edotecarine | ChEMBL registry synonym — accepted as the source's own label CHEMBL435191 ↗ |
| Known as | J-107088 | ChEMBL registry synonym — accepted as the source's own label CHEMBL435191 ↗ |
| Known as | PF-804950 | ChEMBL registry synonym — accepted as the source's own label CHEMBL435191 ↗ |
| Known as | PHA-782615 | “A Phase II Study Of Intravenous Edotecarin (PHA-782615) In Patients With Anthracycline- And Taxane Resistant Metastatic Breast Cancer” NCT00067314 ↗1“A Phase I Dose Escalation Study of Edotecarin (PHA-782615) and Cisplatin in Adult Patients With Advanced/Metastatic Solid Tumors” NCT00072332 ↗ |
| Action | Inhibit | “DNA topoisomerase I inhibitor” CHEMBL435191 ↗ |
| Modality | Small molecule | — CHEMBL435191 ↗ |
| Route | Intravenous | “Intravenous Edotecarin” NCT00067314 ↗ |
| Target | TOP1 | “DNA topoisomerase I inhibitor” CHEMBL435191 ↗ |